ACORDA THERAPEUTICS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.255 USD | -7.27% |
|
+2.00% | -98.31% |
| 12/06 | Motion for Asset Sale Approved for Acorda Therapeutics, Inc. | CI |
| 14/05 | Acorda Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 119M 9.9B | Sales 2023 | 118M 9.83B | Capitalization | 18.74M 1.57B |
|---|---|---|---|---|---|
| Net income 2022 | -65M -5.43B | Net income 2023 | -253M -21.13B | EV / Sales 2022 | 1.3 x |
| Net Debt 2022 | 135M 11.31B | Net Debt 2023 | 161M 13.44B | EV / Sales 2023 | 1.53 x |
| P/E ratio 2022 |
-0.23
x | P/E ratio 2023 |
-0.07
x | Employees | 102 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.33% |
More Fundamentals
* Assessed data
More news
Latest transcript on Acorda Therapeutics, Inc.
| 1 day | -7.27% | ||
| 1 week | +2.00% | ||
| Current month | -35.44% | ||
| 1 month | -70.00% | ||
| 3 months | -97.89% | ||
| 6 months | -98.29% | ||
| Current year | -98.31% |
1 week
0.25
0.30
1 month
0.230.78
Current year
0.2318.00
1 year
0.2318.21
3 years
0.23127.20
5 years
0.23969.60
10 years
0.235 454.00
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/24/21 | 0.2783 | +9.14% | 5,104 |
| 20/24/20 | 0.255 | -7.27% | 10,026 |
| 18/24/18 | 0.275 | +12.24% | 15,551 |
| 17/24/17 | 0.245 | -2.00% | 624 |
| 14/24/14 | 0.25 | -3.10% | 4,280 |
End-of-day quote OTC Markets, June 20, 2024
More quotes
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinsonâs disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
Calendar
01/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -98.31% | 346K | |
| +15.19% | 121B | |
| +19.91% | 114B | |
| +8.24% | 23.61B | |
| -19.80% | 20.43B | |
| -16.19% | 16.55B | |
| -13.45% | 16.45B | |
| -44.35% | 15.59B | |
| +2.13% | 13.54B | |
| +66.67% | 15.19B |
- Stock Market
- Equities
- ACOR.Q Stock
